Loading quotes...
Forecast
There is no analyst data available for this company.
Discussions in the community
There is no discussion about this asset yet.
Start discussionNews Go to news feed
There is currently no news available for this company. We are working on adding more providers to change this.
Financials
| (EUR) | June 2026 | YoY |
|---|---|---|
| Revenue | 63K | - |
| Gross profit | -3.34M | - |
| Net profit | -7.4M | - |
| EBITDA | -6.18M | - |
Fundamentals
| Metric | Value |
|---|---|
Market capitalization | €19.91M |
Number of shares | 77.78M |
52-week high/low | €1.12 - €0.25 |
| Dividends | No |
Beta | 0.21 |
P/E ratio | -1.83 |
PEG ratio | 82,351,536,043,346.20 |
P/B ratio | -3.72 |
P/S ratio | 316.07 |
Company profile
Amoéba S.A. develops and sells biocidal and fungicide products. It is developing around multiple applications using the amoeba Willaertia magna C2c Maky in the prevention of microbiological risk for water treatment, human wounds, and plant protection. The company was founded in 2010 and is headquartered in Chassieu, France.
| Name | Amoeba Aktie |
| CEO | Jean-Francois Doucet |
| Headquarters | Chassieu,
ar France |
| Website | |
| IPO | 07/10/2015 |
| Employees | 23 |
Deep Dive
Ticker symbols
| Exchange | Symbol |
|---|---|
Euronext | ALMIB.PA |
Frankfurt | A1H.F |
London | 0RAE.L |
Paris | ALMIB.PA |
München | A1H.MU |
Düsseldorf | A1H.DU |